Printer Friendly

Cardiovascular Systems' 12-Month Data from COMPLIANCE 360x Study of above-the-Knee Peripheral Arterial Disease Presented at ACC.

Favorable results of the Diamondback(TM) Orbital Atherectomy System compared to balloon angioplasty alone included:

* Freedom from bailout stenting of 92 percent compared to 16 percent

* Freedom from restenosis or retreatment, including the need for bailout stenting, of 73 percent versus 8 percent at 6 months

* Comparable 12-month patency with far less need for adjunctive stenting in the Diamondback arm

ST. PAUL, Minn. & CHICAGO -- Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), today presented 12-month data from the COMPLIANCE 360x study of severely calcified above-the-knee lesions at the American College of Cardiology's (ACC) 61st Annual Scientific Session. Dr. Raymond Dattilo, St. Francis Health Center, Topeka, Kan., principal investigator of the study, presented the long-term data (Abstract Presentation #1123-37) demonstrating that strong acute results translate into positive clinical outcomes at 12 months.

COMPLIANCE 360x enrolled 50 patients (with 65 lesions) at nine U.S. sites. Patients had calcified above-the-knee lesions greater than or equal to 70 percent, and were equally randomized to PTA alone versus therapy with the Diamondback Orbital Atherectomy System. Click here to read the full abstract.

Dr. Dattilo presented the following 12-month data:

Diamondback Arm


(25 pts)

(25 pts)

Procedural Success: 30% residual stenosis without bailout stent placement

92.1% of 38 lesions

21.4% of 28 lesions

Bailout stenting:

2 of 25 patients (8%)

21 of 25 patients (84%)

Mean maximum balloon pressure: (p < 0.0001) (measure of lesions compliance)

3.97 atm

9.15 atm

Percentage of patients free from target lesion revascularization (TLR) or duplex ultrasound restenosis at 12 months:

15 of 20 patients (75%)

16 of 21 patients (76.2%)

Dr. Dattilo noted, "At 12 months, data from COMPLIANCE 360x shows outcomes, treating calcified lesions above-the-knee, consistent with other available data regarding the efficacy of this therapy. Vessel preparation with CSI's Diamondback Orbital Atherectomy System, through compliance change, enables low-pressure adjunctive balloon inflation compared to the high pressures required in the PTA arm. Favorable acute angiographic results led to sustained patency at 12 months in the Diamondback arm that is comparable to PTA with adjunctive stent usage (only 8 percent vs. 84 percent of patients required stenting in each arm, respectively). Decreasing the need for adjunctive stenting preserves future treatment options for patients. Evidence continues to build that we can achieve positive clinical outcomes by changing lesion compliance and decreasing acute vessel injury with CSI's Diamondback Orbital Atherectomy System."

David L. Martin, CSI president and chief executive officer, added: "CSI is focused on treating patients with calcified disease in their arteries. The prevalence of arterial calcium is high in patients over 65 years of age who are diabetic, and/or have renal insufficiency. We are excited to offer both patients and payors a clinically proven product that provides durable outcomes. Our technology is safe, durable, and routinely treats calcium in less than 2 minutes of device run time."

About Peripheral Arterial Disease As many as 12 million Americans, most over age 65, suffer from PAD, which is caused by the accumulation of plaque in peripheral arteries (commonly the pelvis or leg) reducing blood flow. Symptoms include leg pain when walking or at rest. Left untreated, PAD can lead to severe pain, immobility, non-healing wounds and eventually limb amputation. With risk factors such as diabetes and obesity on the rise, the prevalence of PAD is growing at double-digit rates.

Millions of patients with PAD may benefit from treatment with the Diamondback Orbital Atherectomy System, a minimally invasive catheter system developed and manufactured by CSI. This system uses a diamond-coated crown, attached to a guide wire, which sands away plaque while preserving healthy vessel tissue, or medial integrity -- a critical factor in preventing reoccurrences. Balloon angioplasty and stents have significant shortcomings in treating hard, calcified lesions. Stents are prone to fractures and high recurrence rates, and treatment of hard, calcified lesions often leads to vessel damage and suboptimal results.

About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's Diamondback Orbital Atherectomy System treats calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital Atherectomy System in August 2007. To date, more than 61,000 PAD procedures have been performed using CSI's technology in leading institutions across the United States. CSI has also commenced its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its orbital technology in treating coronary arteries. The coronary system is limited by federal law to investigational use and is currently not commercially available in the United States.

For more information, visit the company's website at

Product Disclosure The Diamondback Orbital Atherectomy System is indicated for use as therapy in patients with occlusive atherosclerotic disease in peripheral arteries and stenotic material from artificial arteriovenous dialysis fistulae. The system is contraindicated for use in coronary arteries, bypass grafts, stents or where thrombus or dissections are present. Although the incidence of adverse events is rare, potential events that can occur with atherectomy include: pain, hypotension, CVA/TIA, death, dissection, perforation, distal embolization, thrombus formation, hematuria, abrupt or acute vessel closure, or arterial spasm.
COPYRIGHT 2012 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1U4MN
Date:Mar 24, 2012
Previous Article:Data Presented at ACC Reinforce Positive Clinical Outcomes for Patients Receiving Medtronic's CoreValve[R] System.
Next Article:In TRA-2P Study, Adding Merck's Vorapaxar to Standard of Care Significantly Reduced the Risk of Cardiovascular Events.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters